

RESEARCH MONOGRAPH . COMPOUND PROFILE

Follistatin 315

A 315-residue isoform of follistatin with reduced heparin binding and longer plasma half-life than follistatin 344.

DOCUMENT	KDC-MN-090
ISSUED	2026-05-09
REVISION	1.0
AUTHOR	Kodi ac bio l abs Research
COMPOUND CLASS	Myostatin antagonist / follistatin isoform

RESEARCH USE ONLY

ABSTRACT

Follistatin 315 is a 315-residue isoform of follistatin produced by alternative splicing of the FST gene, lacking the C-terminal acidic region present in follistatin 344. The compound has reduced heparin binding (which improves plasma circulation; follistatin 344 is largely tissue-bound through cell surface heparan sulfate) and a longer plasma half-life. Like follistatin 344, the compound antagonizes myostatin (GDF-8) and activin A. The compound is sold as a research peptide. There is no formal clinical development record. Investigational doses parallel follistatin 344; safety considerations are similar.

1. Compound Identification

Follistatin 315 is described as myostatin antagonist / follistatin isoform. A 315-residue isoform of follistatin with reduced heparin binding and longer plasma half-life than follistatin 344.

1.1 Class summary

Myostatin antagonist / follistatin isoform

1.2 Subtitle

A 315-residue isoform of follistatin with reduced heparin binding and longer plasma half-life than follistatin 344.

2. Abstract

Follistatin 315 is a 315-residue isoform of follistatin produced by alternative splicing of the FST gene, lacking the C-terminal acidic region present in follistatin 344. The compound has reduced heparin binding (which improves plasma circulation; follistatin 344 is largely tissue-bound through cell surface heparan sulfate) and a longer plasma half-life. Like follistatin 344, the compound antagonizes myostatin (GDF-8) and activin A. The compound is sold as a research peptide. There is no formal clinical development record. Investigational doses parallel follistatin 344; safety considerations are similar.

3. Mechanism of Action

Endogenous myostatin/activin antagonist; longer half-life than follistatin 344.

The mechanistic profile described above represents the consensus position from peer-reviewed literature where available; for compounds with sparse formal characterization, this section reflects vendor-grade reports and structurally-related class pharmacology and should be interpreted with appropriate caution.

4. Pharmacokinetics and Routes of Administration

Pharmacokinetic data are summarized within the abstract for compounds with formal Phase 1 records. Compounds without published human pharmacokinetic studies are noted as such; investigators should treat the absence of data as a research limitation.

5. Reported Research Dose Ranges

100 micrograms to 1 mg per day SC/IM (research-grade).

Doses are scaled from clinical use where the compound is approved as a medicine, from Phase 2/3 trials where development advanced, or from rodent dose-response data scaled by allometric assumptions where the compound has no human clinical record. Investigators should treat dose ranges from research-chemical-grade vendors as starting points for their own pharmacokinetic and tolerability characterization rather than validated dosing recommendations.

6. Sourcing and Quality Verification

Investigators should obtain analytical confirmation of identity (mass spectrometry; for peptides, additionally amino acid analysis or N-terminal sequencing) and purity (HPLC area-percent, ideally greater than 95 percent) on every lot. Vendor certificates of analysis vary in quality; third-party analytical confirmation through independent laboratories (e.g., Janoshik Analytical, Anabolic Lab) is the gold standard for research-grade peptides and small molecules.

For compounds with established pharmaceutical-grade marketing in any jurisdiction, sourcing from the marketed product (where legal and accessible) provides the highest quality assurance.

7. Reconstitution and Handling

Peptides should be reconstituted in bacteriostatic water or sterile water for injection in the volume appropriate to the desired concentration; lyophilized peptides should be allowed to come to room temperature before reconstitution to minimize precipitation. Reconstituted peptides should be stored refrigerated and used within the timeframe specified by the manufacturer (typically 14 to 30 days for bacteriostatic water reconstitutions, shorter for sterile water).

Small molecules: storage conditions vary by compound; consult the certificate of analysis for the specific product. Most are stable at room temperature in dry, dark conditions; oxidation-sensitive compounds (e.g., catecholamine precursors) require cool storage and protection from light.

8. Stack Interaction Considerations

Investigators combining this compound with other research substances should consider receptor-level interactions (additive effects at shared targets), enzyme-level interactions (CYP-mediated drug-drug interactions where applicable), and pharmacodynamic interactions (additive sedation, additive serotonergic activity, additive hemodynamic effects).

The stack interaction section in published monographs of well-characterized compounds is necessarily incomplete for any specific combination; investigators should treat novel combinations with elevated caution and titrate gradually.

9. References

1. Welt C, et al. The follistatin family. Endocrinology 2006.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly.